Kornimate/medical-research-clean huggingface dataset:
external oblique and rectus abdominis plane (exora) block for postoperative analgesia in patients undergoing umbilical hernia repair

Conditions: External Oblique and Rectus Abdominis Plane; Postoperative Analgesia; Umbilical Hernia Repair

Summary: this study aims to evaluate the effect of the external oblique and rectus abdominis plane (exora) block for postoperative analgesia in patients undergoing umbilical hernia repair.

umbilical hernias account for approximately 6-14% of adult abdominal wall hernias. these hernias are typically acquired and are mainly caused by increased abdominal pressure. umbilical hernias do not heal on their own and usually require surgical intervention. the external oblique and rectus abdominis plane (exora) block is an emerging technique providing a sensory block to the anterolateral abdominal wall. the exora block involves local anaesthetic injection into the fascial plane between the external oblique and rectus abdominis muscles. this method provides better dermatomal coverage, making the exora block particularly effective in the treatment of somatic pain in the anterolateral area of the upper and middle abdomen.

Eligibility criteria:
inclusion criteria: * age from 18 to 65 years. * both sexes. * american society of anesthesiology (asa) physical status i-ii. * undergoing umbilical hernia repair. exclusion criteria: * history of allergies to local anesthetics. * bleeding or coagulation disorders. * anatomical abnormalities. * psychiatric and neurological disorders. * local infection at the site of injection. * complicated hernial defects \[strangulated, incarcerated, or obstructed cases\].
study of krt-232 or tl-895 in janus associated kinase inhibitor treatment-naïve myelofibrosis

Conditions: Primary Myelofibrosis (PMF); Post-Polycythemia Vera Myelofibrosis (Post-PV-MF); Post-Essential Thrombocythemia Myelofibrosis (Post-ET-MF)

Summary: this study evaluates either krt-232 or tl-895 in treatment naïve patients with myelofibrosis (mf) the study will be conducted in 2 stages. stage 1 will evaluate safety, tolerability, and efficacy of either krt-232 (arm 1) or tl-895 (arm 2) in treatment naïve patients. stage 2 will expand enrollment in arm 1 and/or arm 2 if expansion criteria is met.


Eligibility criteria:
inclusion criteria: * confirmed diagnosis of pmf, post-pv mf or post-et mf (who) * high-risk, or intermediate-1 and 2 risk, defined by dynamic international prognostic system (dipss) * ecog of 0 or 1 exclusion criteria: * subjects who are positive for p53 mutation (arm 1) * prior mdm2 inhibitor therapy or p53-directed therapy (arm 1) * prior treatment with any jak inhibitor * prior splenectomy * splenic irradiation within 24 weeks prior to randomization * prior allogeneic stem-cell transplantation or plans for allogeneic stem-cell transplant * history of major organ transplant * grade 2 or higher qtc prolongation * major hemorrhage or intracranial hemorrhage within 24 weeks prior to randomization

Keywords: navtemadlin
vcsip follow-up study

Conditions: Asthma; Pulmonary Function; Wheezing; In Utero Nicotine

Summary: the overall aims of this protocol are to determine whether prenatal supplementation with vitamin c to pregnant smokers can improve pulmonary function and decrease wheeze at 5 years of age in their offspring. this is a continuation of the vcsip trial, to follow the offspring through 5 years of age. the hypothesis for this protocol is an extension of the vcsip trial that supplemental vitamin c in pregnant smokers can significantly improve their children's pfts and decrease the incidence of wheeze.

the overall aims of this protocol are to determine whether prenatal supplementation with vitamin c to pregnant smokers can improve pulmonary function and decrease wheeze at 5 years of age in their offspring. this is a continuation of the vcsip trial, to follow the offspring through 5 years of age. the hypothesis for this protocol is an extension of the vcsip trial that supplemental vitamin c in pregnant smokers can significantly improve their children's pfts and decrease the incidence of wheeze. the reasons for this protocol are to follow the children born to mothers randomized in the vcsip to the age of 5 to differentiate the patients with transient versus recurrent wheeze (and therefore more likely to develop asthma); to determine if early protective effects of vitamin c are sustained to this older age; and to continue to collect biologic samples from the children for future mechanistic studies of vitamin c action. the primary aim of this study is to demonstrate improved pulmonary function at 5 years of age in the offspring of pregnant smokers randomized to vitamin c (500 mg/day) versus placebo. the investigators hypothesize that vitamin c supplementation in pregnancy will block the adverse effects of maternal smoking on offspring pulmonary function measured at 5 years of age by spirometry. impulse oscillometry (ios) will also be used at 3-5 years of age to assess pulmonary function. specific aim 2 (secondary outcome): the secondary aim of this study is to demonstrate a decreased incidence of wheeze at 5 years of age in offspring of pregnant smokers randomized to vitamin c (500 mg/day) versus placebo. the investigators hypothesize that vitamin c supplementation during pregnancy will decrease the incidence of wheeze at 5 years of age in offspring of smokers. respiratory health will be assessed by quarterly validated respiratory questionnaires and clinician report.

Eligibility criteria:
inclusion criteria: * women and their offspring randomized to vitamin c versus placebo during pregnancy as well as pregnant nonsmokers and their offspring enrolled as the reference group in the current rct. exclusion criteria: * patients specifically withdrawing consent.

Keywords: asthma pulmonary function testing wheeze vitamin c antioxidants forced expiratory flows
high-definition tdcs treatment for cantonese-speaking adults who stutter

Conditions: Stuttering, Adult; Stammering

Summary: the proposed study aims to investigate the effect of combined transcranial direct current stimulation (tdcs) and behavioural speech training in improving speech fluency in cantonese-speaking adults who stutter (aws), and to examine its maintenance over a 6-week period.

the proposed study aims to 1. assess the effect of multiple sessions of tdcs over the supplementary motor area (sma) combined with behavioural speech training on stuttering recovery in terms of a reduction of stuttering severity and increased speech satisfaction in cantonese-speaking aws; 2. investigate the maintenance of combined tdcs-behavioural speech training effects on speech fluency and speech satisfaction in cantonese-speaking aws over a 6-week period. twenty cantonese-speaking aws will be randomly assigned to an experimental group and a control group. both groups will receive behavioral treatment for stuttering, including the speech prolongation technique, for five sessions. concurrent with behavioural training, the experimental group will receive anodal tdcs (1 ma for 20 minutes), while the control group will receive sham tdcs (1 ma for one minute), over the sma. stuttering severity and speech satisfaction will be assessed independently before, immediately after, one week and six weeks after treatment. it is anticipated that aws will experience reduction in their stuttering severity after stimulation, and the improvement will be maintained for a longer period as compared with receiving behavioural treatment alone.

Eligibility criteria:
inclusion criteria: * demonstrated features of stuttering; * more than 2% of syllables stuttered over three baseline speech samples, as measured by qualified speech therapists. exclusion criteria: * personal or family history of epilepsy or seizures * history of a neurological condition * speech disorders * hearing impairment * metallic foreign body implant * on medications that lower neural thresholds (e.g. tricyclines, antidepressants, neuroleptic agents, etc.) * pregnant * had speech therapy for stuttering in the past four months

Keywords: tdcs stuttering speech therapy camperdown program
outcome evaluation of minority aids initiative programs in the new york ema

Conditions: HIV Infections

Summary: this outcome evaluation effort provides the opportunity to learn what programmatic approaches effectively address two of the most difficult hurdles in hiv health services delivery: (1) getting people who would benefit from health care to use it and (2) getting people who do use health care to do so more consistently and effectively. the new york hiv planning council (through mhra) has funded 23 agencies to achieve these objectives for people of color with hiv disease.

all clients are assessed upon entry into the program, have their service utilization tracked, and then are reassessed at three, six, and twelve months following program entry. the main client-level data elements collected during baseline and follow-up interviews are the following: * biological markers (including hiv status, viral load, t-cell count) * demographic characteristics * adherence to treatment * barriers to care * social support * substance use and treatment * functional health status functional health status is used in this evaluation as the primary measure of final client "outcomes." the functional health status items we use are from the actg sf-21 (a modified version of the medical outcomes study instrument). the overall evaluation objectives are to: * describe the change in functional health status for different populations and groups of clients. * identify services or constellations of services and intensity of services associated with change in functional health status. * assess whether programs meet intermediate objectives (decreased drug use, increased service use, improved housing stability). * identify barriers to access to and maintenance in care.

Eligibility criteria:
inclusion criteria: * hiv-positive * not in hiv care, or difficulty being maintained in hiv care * hiv-negative but at high risk of hiv infection exclusion criteria: * hiv-negative and not at high risk of hiv infection

Keywords: hiv minority groups health services accessibility quality of life
effect of stress ball on perceived stress, pain and satisfaction in cancer patients

Conditions: Cancer

Summary: the objective of this study was to ascertain the impact of stress ball utilisation on perceived stress, pain and satisfaction levels during port catheter intervention in cancer patients. in this study, which was conducted in a randomised controlled design, a control group of cancer patients receiving chemotherapy (n=37) was assigned to receive standard care during port catheter needle insertion. an intervention group (n=37) was also formed, comprising patients who received stress ball application in addition to standard care. the intervention group was provided with a stress ball in both hands five minutes prior to the insertion of the port catheter needle and instructed to squeeze the ball in their hands at regular intervals until the conclusion of the procedure. prior to the application, the descriptive characteristics of both groups were ascertained, and their perceived stress levels were assessed. subsequently, the pain and perceived stress levels of both groups were documented. additionally, the satisfaction levels of the intervention group regarding the stress ball application were evaluated.


Eligibility criteria:
inclusion criteria: * 18 years and older * diagnosed with cancer * undergoing active chemotherapy * willing to participate in the research . exclusion criteria: * communication difficulties * complaints of peripheral neuropathy * refusal to participate in the research

Keywords: cancer patient perceived stress pain patient satisfaction
learning lab for diagnostic fidelity

Conditions: Critical Illness

Summary: diagnostic error and delay remain a leading cause of preventable harm and death in the united states. using a learning laboratory structure, researchers will implement mixed-methods research approaches to identify the systemic weaknesses that contribute to diagnostic error and delay in the hospital setting. the knowledge gained from research innovative will allow researchers to design, develop, implement, and refined a suite of human-centered tools that can be deployed to reduce the risk of diagnostic error and delay in both community and academic hospital settings.

despite the recognition that diagnostic errors an delays are a major contributor to preventable deaths in the usa, little progress has been made to reduce mortality outcomes from this known killer. an effective strategy leading to meaningful reduction in diagnostic error and delay rates has not made its way into practice. this proposal is unique and novel and combines mixed-methods research approaches with systems engineering research approaches to understand the interplay of the multiple factors contributing to diagnostic error and delay. the knowledge gained from this holistic approach will then be used within the learning laboratory to inform the design, development, evaluation, and refinement of the solutions to diagnostic error and delay. "control tower" will be the staging ground for the in situ learning laboratory and will be built on top of a well-established clinical informatics infrastructure and hospital environment open to innovation and practice change.

Eligibility criteria:
inclusion criteria * for emr review all adults admitted to the hospital ages 18 and older with research authorization * for survey-clinicians including physicians, advanced care practitioners * for focus groups and interviews-clinicians including physicians, advanced care practitioners exclusion criteria * age \<18 years old * no research authorization * refusal to give consent

Keywords: critical illness patient safety delivery of health care electronic health records
impact of renal function availability to community pharmacist for dispensing direct oral anticoagulant in ambulatory patients on bleeding occurrence

Conditions: AOD Prescription

Summary: the use of direct oral anticoagulants (aods) in the prevention and treatment of thromboembolic diseases is increasing, with a favorable benefit/risk balance and improved quality of life for patients. however, anticoagulants are still associated with a risk of bleeding, making them one of the drugs most likely to cause adverse events and serious adverse events. certain clinical situations are particularly at risk of bleeding with aods, notably renal failure (even moderate) and age over 75, due to the predominant renal elimination of these drugs. prescription and monitoring of aod treatment are conditional on monitoring of renal function and, if necessary, appropriate dosage adjustments. community pharmacists dispense aods on a daily basis, following pharmaceutical analysis. good dispensing practice recommends that community pharmacists have access to biological data. studies have suggested that access to renal function enables community pharmacists to carry out targeted and appropriate interventions. this expected clinical pharmaceutical expertise is conditional on access to this biological data. in practice, community pharmacists are not systematically aware of this renal function, and are therefore unable to carry out a pharmaceutical intervention if necessary. initiatives implemented by general practitioners seem to be emerging (systematic addition of the renal to the medical prescription), but these practices do not currently guarantee systematic access to this data. a strong argument in favor of systematically making the renal available to community pharmacists would be to demonstrate that access to this biological data reduces the occurrence of adverse events linked to aods.

the main objective is to study the benefit of access to the patient's renal function by the dispensing pharmacist when dispensing an aod (first prescription or renewal) on the occurrence of clinically significant bleeding at 3 months.

Eligibility criteria:
inclusion criteria: * with a prescription for an aod (first prescription or renewal), * whatever the indication of the aod treatment, * coming to one of the study's partner pharmacies for dispensing, * adults, * agreeing to take part in the study (by signing the informed consent form). exclusion criteria: * prescribed another class of anticoagulant, * minors, * pregnant and breast-feeding women * who do not understand french * protected by law (guardianship, curatorship, safeguard of justice), * refusing to take part in the study.

Keywords: community pharmacist aod renal function bleeding
mmr and mmrv vaccines: effect of age at first dose on safety and immunogenicity of the measles component.

Conditions: Measles

Summary: healthy children who received two doses of glaxosmithkline (gsk) biologicals' live attenuated measles-mumps-rubella vaccine (mmr) or measles-mumps-rubella-varicella vaccine (mmrv) in their second year of life.the purpose of this study is to assess the effect of the age at administration of the first dose on the reactogenicity and immunogenicity of the measles component of these vaccines. in addition, this study will evaluate if the effect of the age at first dose is modified by the type of vaccine administered.


Eligibility criteria:
inclusion criteria: * healthy male or female subject between 11 to 22 months at the time of first vaccination. * written informed consent obtained from the parent/guardian of the subject. exclusion criteria: * history of previous measles, mumps, rubella and/or varicella vaccination or disease or known exposure to any of these diseases within 30 days prior to the inclusion in the study. * any confirmed or suspected immunosuppressive or immunodeficient condition, included the chronic administration (defined as more than 14 days) of immune-suppressants or other immune-modifying drugs within six months prior to the firs vaccine dose. * history of any neurologic disorders or seizures. * history of allergic diseases or reactions likely to be exacerbated by any component of the vaccines. * planned administration of a vaccine not foreseen by the study protocol from 30 days prior to each vaccination until 42-56 days after each vaccination

Keywords: measles vaccine priorix priorix-tetra age at vaccination
can1012 combined with pd-1 in patients with solid tumors

Conditions: Advanced Solid Tumor

Summary: this is a phase ia/iib, open-label, first-in-human, multicenter, single-arm, dose escalation study of intratumoral can1012 combined with pd-1 in patients with unresectable or metastatic advanced solid tumors who have exhausted options for standard of care therapy.

the scope of the study is to evaluate the safety of the combination therapy of can1012 and pd-1 in human, study its efficacy and pharmacokinetics profiles, as well as explore its pharmacodynamic effects and biomarkers.

Eligibility criteria:
inclusion criteria: 1. able and willing to provide written informed consent and willing to comply with the study's requirements. 2. male or female age ≥ 18 years at screening. 3. patients with histologically and cytologically confirmed locally advanced or metastatic solid tumors who have been refractory or intolerant to standard therapies or for whom no standard therapy exists. 4. metastatic or locally advanced solid tumor that has progressed on, is refractory to, or for which there is no efficacious standard of care therapy. preferred tumor types include the following: carcinoma of skin, melanoma, merkel cell carcinoma (mcc), breast cancer, head and neck squamous cell carcinoma (hnscc), sarcoma, cervical carcinoma, and colorectal cancer 5. performance status of 0-1 on the ecog performance scale. exclusion criteria: 1. unresolved toxicities from prior therapy, defined as having not resolved to common terminology criteria for adverse events (ctcae) version 5.0 (v5.0) grade 0 or 1, with exception of endocrinopathies from prior therapy, alopecia, and vitiligo. 2. treatment with systemic corticosteroids at doses exceeding 10 mg/day prednisone or equivalent. 3. has an active infection requiring systemic therapy. 4. unstable/inadequate cardiac function defined as follows: 1. new york heart association class 3 or 4 congestive heart failure 2. uncontrolled hypertension 3. acute coronary syndrome within 6 months 4. clinical important cardiac arrhythmia 5. mean corrected qt (qtc) interval corrected for heart rate \>450msec（male），\>470msec（female）. 5. a history of interstitial lung disease. 6. a history of coagulopathy resulting in uncontrolled bleeding or other bleeding disorders. 7. participated in a clinical study of an investigational agent within 30 days of screening. 8. has known psychiatric, substance abuse, or other disorders that would interfere with cooperation with the requirements of the study in the opinion of the investigator. 9. is pregnant or breastfeeding.
validation of the chinese version of the sinus and nasal quality of life survey (sn-5)

Conditions: Chronic Rhinosinusitis

Summary: the purpose of our study was to validate the chinese version of the sinus and nasal quality of life survey (sn-5)and correlation with the incidence of pediatric obstructive sleep apnea and asthma. the study will enroll pediatric patients of rhino-sinusitis and their parents to finish questionnaire 1, including chinese version of sn-5, visual analogue scale (vas), pediatric allergy disease pediatric allergic disease quality of life questionnaire (padqlq), osa-18 quality of life survey, and asthma-diagnostic questionnaire . some patients re-tested sn-5 in 1 week later. after four weeks, participants finish these questionnaire 2, including sn-5, vas, and padqlq. in addition, the author will invite health children without rhino-sinusitis disease and their parents to fill in questionnaire 1. the chinese version of sn-5 will be validated to establish its reliability and validity.

the purpose of the study was to validate the chinese version of the sinus and nasal quality of life survey (sn-5)and correlation with the incidence of pediatric obstructive sleep apnea and asthma. the study will enroll pediatric patients of rhino-sinusitis and parents to finish questionnaire 1, including chinese version of sn-5, visual analogue scale (vas), pediatric allergy disease pediatric allergic disease quality of life questionnaire (padqlq), osa-18 quality of life survey, and asthma-diagnostic questionnaire . some patients re-tested sn-5 in 1 week later. after four weeks, they finish these questionnaire 2, including sn-5, vas, and padqlq. in addition, the author will invite health children without rhino-sinusitis disease and their parents to fill in questionnaire 1. the chinese version of sn-5 will be validated to establish its reliability and validity. from december 2016 to december 2017, healthy volunteers and children with persistent sinonasal symptoms were enrolled. guardians of the participants completed the sn-5, a visual analog scale (vas) of nasal symptoms, and the obstructive sleep apnea-18 (osa-18) ; the responses were used to assess internal consistency, discriminant validity, and treatment responsiveness. a nontreatment group was administered the sn-5 1 week later to assess test-retest reliability.

Eligibility criteria:
inclusion criteria: children with one or more of the following symptoms, purulent nasal discharge, nasal congestion, cough, or postnasal drip for at least 1 month. exclusion criteria: * craniofacial anomalies * cognitive deficits * illiteracy in traditional chinese.

Keywords: sn-5 quality of life children